https://www.selleckchem.com/
07, 95%CI 1.08-23.69, p=0.039) but EGFR mutation status was not. For the EGFR+ cohort, patients with disease progression after initial management on a TKI had a worse response rate compared to patients who were TKI-naïve before starting radiotherapy (30 vs. 77%, p=0.018). Local control was not statistically different between the EGFR cohorts. The EGFR mutation status alone was not an independent predictor of objective radiographic response to palliative thoracic radiotherapy. Acquired resistance to TKI therapy may be associated with disease cross-resistance
Like
Comment
Share
